FDA Approval and Product Overview - The FDA has approved INNOVATE Corp's MediBeacon TGFR for assessing kidney function in patients with normal or impaired renal function [1] - The TGFR system includes a sensor, monitor, and Lumitrace injection, which measures kidney function by tracking the clearance rate of a fluorescent agent [2] - The system records fluorescence intensity transdermally at 2.5 readings per second and displays average session tGFR readings at the patient's bedside [2] Clinical Advantages and Validation - The TGFR eliminates the need for blood draws or urine analysis, unlike current GFR assessment methods [3] - It has been validated for use in patients with stable kidney function at the point of care [3] - The TGFR met its primary efficacy endpoint with a P30 value of 94%, indicating high accuracy in GFR estimation [5] - Clinical studies showed no serious or severe adverse events [6] Industry Impact and Expert Opinions - The TGFR represents a significant milestone for nephrology, offering a non-invasive method to assess kidney function [4] - Experts highlight its potential to improve clinical practice, particularly in cases where current methods are suboptimal [4] - Chronic Kidney Disease (CKD) affects over 800 million people globally and is a leading cause of mortality [7] Company and Product Background - INNOVATE Corp operates in Infrastructure, Life Sciences, and Spectrum, employing approximately 4,000 people [8] - MediBeacon, a subsidiary, specializes in fluorescent tracer agents and transdermal detection technology, holding over 55 U.S. patents and 215 worldwide [9] - Lumitrace injection, a key component of the TGFR, has been administered to over 850 subjects and is designed for non-invasive GFR measurement [10] Technical and Safety Information - The TGFR is not approved for patients with GFR <15ml/min/1.73m2 or >120ml/min/1.73m2, or for those on dialysis [13] - Lumitrace injection may interfere with clinical laboratory tests, and its use is contraindicated in patients requiring such tests within 72 hours [17]

NEW YORK, Nov. 20, 2024 (GLOBE NEWSWIRE) -- R2 Technologies, Inc., the world leader in CryoAesthetics® with its cutting-edge Glacial Skin systems (“R2”), a portfolio company of INNOVATE Corp. (NYSE: VATE) (“INNOVATE” or the “Company”) announced today that it has achieved several impressive milestones during 2024. The growing momentum of the brand coupled with recent key partnerships has positioned the company for substantial growth across the aesthetics and wellness sectors. Celebrating the one-year anniver ...

INNOVATE Corp. (NYSE:VATE) Q3 2024 Earnings Conference Call November 6, 2024 4:30 PM ET Company Participants Anthony Rozmus - Investor Relations Paul Voigt - Interim Chief Executive Officer Mike Sena - Chief Financial Officer Conference Call Participants Brian Charles - R.W. Pressprich Operator Good afternoon, and welcome to INNOVATE Corp. Third Quarter 2024 Earnings Conference Call. All participants will be in a listen-only mode. [Operator Instructions] Please note, this event is being recorded. I would no ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. For the quarterly period ended September 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. Commission File No. 001-35210 INNOVATE CORP. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation or organization) 295 Madison Ave., 12th ...

FOR IMMEDIATE RELEASE INNOVATE Corp. Announces Third Quarter 2024 Results - Infrastructure: DBM Global third quarter revenue of $232.8 million - - Life Sciences: R2 reports record worldwide system unit sales growth in the third quarter - - Spectrum: Broadcasting's delivered another quarter of strong growth driven by network launches - NEW YORK, NY, November 6, 2024 - INNOVATE Corp. ("INNOVATE" or the "Company") (NYSE: VATE) announced today its consolidated results for the third quarter. Financial Summary | ...

NEW YORK, Oct. 16, 2024 (GLOBE NEWSWIRE) -- INNOVATE Corp. (NYSE: VATE) ("INNOVATE" or the "Company") announced today that it will release its financial results for the third quarter 2024 on Wednesday, November 6, 2024, after market close. The Company will host an earnings conference call reviewing these results, its operations and strategy on the same day, beginning at 4:30 p.m. ET. Dial-in instructions for the conference call and the replay are outlined below. This conference call will also be broadcast l ...

NEW YORK, Sept. 03, 2024 (GLOBE NEWSWIRE) -- INNOVATE Corp. (NYSE: VATE) ("INNOVATE" or the "Company") announced today that it has received a letter from the New York Stock Exchange ("NYSE") dated August 27, 2024 (the "Compliance Notice"), notifying the Company that it is no longer considered below the NYSE's continued listing criterion of a minimum average share price of US $1.00 over a 30 trading-day period (the "NYSE Minimum Price Requirement"). "The INNOVATE team is pleased to share that we have receive ...

INNOVATE Corp. (NYSE:VATE) Q2 2024 Earnings Conference Call August 7, 2024 4:30 PM ET Company Participants Anthony Rozmus – Investor Relations Paul Voigt – Interim Chief Executive Officer Mike Sena – Chief Financial Officer Conference Call Participants Brian Charles – R.W Operator Good afternoon, and welcome to the INNOVATE Corporation’s Second Quarter 2024 Earnings Conference Call. All participants will be in a listen-only mode. [Operator Instructions] Please note, this event is being recorded. And now I w ...

INNOVATE Corp. INNOVATE Q2 2024 Earnings Release Supplement August 7, 2024 INNOVATE Corp. ™ 2024 Safe Harbor Disclaimers Cautionary Statement Regarding Forward-Looking Statements Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: This presentation contains, and certain oral statements made by our representatives from time to time may contain, "forward-looking statements." Generally, forward-looking statements include information describing actions, events, results, strategies ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. For the quarterly period ended June 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. Commission File No. 001-35210 INNOVATE CORP. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation or organization) 295 Madison Ave., 12th Floo ...